Yongsam Lee Sells 10,000 Shares of Masimo Co. (MASI) Stock

Masimo Co. (NASDAQ:MASI) EVP Yongsam Lee sold 10,000 shares of the company’s stock in a transaction dated Friday, January 5th. The stock was sold at an average price of $88.17, for a total value of $881,700.00. Following the sale, the executive vice president now owns 75,018 shares of the company’s stock, valued at $6,614,337.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Yongsam Lee also recently made the following trade(s):

  • On Friday, December 1st, Yongsam Lee sold 5,900 shares of Masimo stock. The shares were sold at an average price of $88.31, for a total value of $521,029.00.
  • On Monday, December 4th, Yongsam Lee sold 18,198 shares of Masimo stock. The shares were sold at an average price of $88.85, for a total value of $1,616,892.30.
  • On Thursday, November 9th, Yongsam Lee sold 13,976 shares of Masimo stock. The shares were sold at an average price of $89.43, for a total value of $1,249,873.68.
  • On Wednesday, November 1st, Yongsam Lee sold 5,000 shares of Masimo stock. The shares were sold at an average price of $89.89, for a total value of $449,450.00.

Masimo Co. (MASI) traded down $1.39 during mid-day trading on Monday, hitting $87.70. The stock had a trading volume of 538,974 shares, compared to its average volume of 390,180. Masimo Co. has a fifty-two week low of $67.85 and a fifty-two week high of $104.71. The firm has a market capitalization of $4,530.00, a price-to-earnings ratio of 13.90, a P/E/G ratio of 3.41 and a beta of 0.72.

Masimo (NASDAQ:MASI) last issued its quarterly earnings data on Tuesday, October 31st. The medical equipment provider reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.53 by $0.17. Masimo had a return on equity of 22.17% and a net margin of 45.83%. The firm had revenue of $193.69 million during the quarter, compared to analyst estimates of $189.01 million. During the same quarter last year, the firm earned $0.52 EPS. Masimo’s quarterly revenue was up 15.6% on a year-over-year basis. research analysts anticipate that Masimo Co. will post 2.95 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently modified their holdings of MASI. DekaBank Deutsche Girozentrale grew its stake in Masimo by 78.3% during the 3rd quarter. DekaBank Deutsche Girozentrale now owns 2,106 shares of the medical equipment provider’s stock valued at $182,000 after purchasing an additional 925 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Masimo by 13.2% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,018 shares of the medical equipment provider’s stock valued at $184,000 after purchasing an additional 236 shares in the last quarter. Advisor Group Inc. grew its stake in Masimo by 38.4% during the 2nd quarter. Advisor Group Inc. now owns 2,361 shares of the medical equipment provider’s stock valued at $216,000 after purchasing an additional 655 shares in the last quarter. Intellectus Partners LLC acquired a new stake in Masimo during the 2nd quarter valued at approximately $237,000. Finally, Shelton Capital Management acquired a new stake in Masimo during the 2nd quarter valued at approximately $269,000. Hedge funds and other institutional investors own 83.69% of the company’s stock.

MASI has been the subject of a number of recent research reports. Stifel Nicolaus reiterated a “buy” rating and issued a $108.00 target price on shares of Masimo in a research note on Friday, November 3rd. Zacks Investment Research upgraded Masimo from a “hold” rating to a “buy” rating and set a $98.00 target price for the company in a research note on Thursday, November 2nd. Finally, BidaskClub lowered Masimo from a “hold” rating to a “sell” rating in a research note on Thursday, December 7th. One research analyst has rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $97.17.

WARNING: This piece of content was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/08/yongsam-lee-sells-10000-shares-of-masimo-co-masi-stock.html.

Masimo Company Profile

Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry.

Insider Buying and Selling by Quarter for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply